05 Feb 2018
LIBERUM: Shield Therapeutics* - Major negative surprise as Phase 3 kidney study fails
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LIBERUM: Shield Therapeutics* - Major negative surprise as Phase 3 kidney study fails
Shield Therapeutics Plc (STX:LON) | 1.3 0 0.0% | Mkt Cap: 10.4m
- Published:
05 Feb 2018 -
Author:
Roger Franklin | Graham Doyle -
Pages:
3